Photofrin (porfimer sodium) / Advanz Pharma - LARVOL DELTA

Transbronchial Photodynamic Therapy for Peripheral Lung Cancer - A Pilot Study. (PubMed, Photodiagnosis Photodyn Ther) - "Lipiodol-assisted transbronchial PDT is technically feasible and demonstrated a favorable acute safety profile in this small pilot cohort. While the low light dose (200 J/cm) resulted in modest tumor control, the technique successfully addressed the challenge of light delivery to peripheral lesions. Future Phase I trials with dose escalation are warranted."

Journal • Infectious Disease • Lung Cancer • Oncology • Pneumonia • Respiratory Diseases • Solid Tumor

Photodynamic Therapy for Central Early-Stage Lung Cancer: A Retrospective Comparative Study of Photofrin, Chlorin e6, and Foscan. (PubMed, Respiration) - "PDT is a safe and effective treatment modality for centrally located early-stage lung cancer, achieving high rates of local tumor control. Among the evaluated photosensitizers, Chlorin e6 showed a favorable balance of efficacy and safety."

Journal • Retrospective data • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Phase I/II Clinical Study of Next-Generation Photodynamic Therapy (L-PDT) Using Talaporfin Sodium (Laserphyrin®) for Cervical Intraepithelial Neoplasia: Efficacy, Safety, and Fertility Preservation. (PubMed, Photodiagnosis Photodyn Ther) - "These results suggest that L-PDT is a safe and highly effective non-excisional treatment for CIN that may contribute to fertility preservation; however, potential advantages over conventional conization and laser vaporization need to be confirmed in comparative studies."

Journal • P1/2 data • Cervical Cancer • Gynecologic Cancers • Gynecology • Oncology • Pain • Solid Tumor

Photodynamic Therapy to Amplify the Response to Immunotherapy in Patients With Non-small Cell Lung Cancer With Pleural Disease (clinicaltrials.gov) - P1 | N=5 | Terminated | Sponsor: Roswell Park Cancer Institute | Active, not recruiting ➔ Terminated; low accrual

Trial termination • Lung Cancer • Malignant Pleural Mesothelioma • Mesothelioma • Non Small Cell Lung Cancer • Oncology • Pleural Mesothelioma • Respiratory Diseases • Solid Tumor • PD-L1

Photodynamic Action of Hypocrellin A and Hypocrellin B against Cancer-A Review. (PubMed, Pharmaceuticals (Basel)) - "There are two types of photosensitizers in PDT, including synthetics (e.g., hematoporphyrin derivative, photofrin II, verteporfin) and natural (e.g., Hypocrellin A (HA) and Hypocrellin B (HB)). "Curcumin" is a successful PS for traditional Chinese medicine used in PDT during clinical study and it is used as a benchmark for HB. Currently, scientists are paying attention to "nanotechnology" that enhances hypocrellin's properties in PDT for achieving clinical goals, but further investigations are required."

Journal • Review • Oncology

Phase II Trial of Radical Pleurectomy With or Without Intraoperative PDT for Malignant Pleural Mesothelioma (clinicaltrials.gov) - P2 | N=52 | Active, not recruiting | Sponsor: Abramson Cancer Center at Penn Medicine | Trial completion date: Dec 2025 ➔ Dec 2027 | Trial primary completion date: Nov 2024 ➔ Dec 2026

Trial completion date • Trial primary completion date • Malignant Pleural Mesothelioma • Mesothelioma • Oncology • Pleural Mesothelioma • Solid Tumor

Safety Profile and Therapeutic Efficacy of Photodynamic Therapy for Early-Stage Endobronchial Carcinoma (ERS 2025) - "The photosensitizers used were Photofrin, Chlorin E6, and Foscan. The study included 36 patients (mean age: 65.4 ± 7.6 years; 19% female; mean FEV1: 51.6 ± 21.1%; mean DLCO: 46.2 ± 21.7%) with 61 lesions, of which 68.9% were multilocular. Fibrin exudation occurred in 90.6% of PDT procedures (n = 53), resulting in complete airway obstruction in 30.2% of cases within the treated area. One patient required prolonged mechanical ventilation due to severe fibrin exudation."

Clinical • Lung Cancer • Oncology • Solid Tumor

Phase II Trial of Radical Pleurectomy With or Without Intraoperative PDT for Malignant Pleural Mesothelioma (clinicaltrials.gov) - P2 | N=52 | Active, not recruiting | Sponsor: Abramson Cancer Center at Penn Medicine | Trial completion date: Jun 2025 ➔ Dec 2025

Trial completion date • Malignant Pleural Mesothelioma • Mesothelioma • Oncology • Pleural Mesothelioma • Solid Tumor

Light Dosimetry for Photodynamic Therapy With Porfimer Sodium in Treating Participants With Malignant Mesothelioma or Non-Small Cell Lung Cancer With Pleural Disease Undergoing Surgery (clinicaltrials.gov) - P1 | N=9 | Active, not recruiting | Sponsor: Roswell Park Cancer Institute | Trial completion date: Oct 2025 ➔ Oct 2026

Trial completion date • Lung Cancer • Mesothelioma • Non Small Cell Lung Cancer • Oncology • Respiratory Diseases • Solid Tumor

Imaging tumor oxygenation during interstitial photodynamic therapy (AACR 2025) - "The objective of this investigational study was to perform electron paramagnetic resonance oxygen imaging (EPROI) during I-PDT of locally advanced murine tumors to investigate how changes in the delivered light irradiance, mW/cm2, correlate to changes in tumor oxygenation. C3H mice with locally advanced squamous cell carcinoma (SCC7), between 260-740 mm3, were treated with I-PDT using the photosensitizer porfimer sodium administered at a dose of 5.0 mg/kg via tail vein injection... The mean pre-treatment pO2 was 9.74 ± 2.37 torr. The average decrease in pO2 as measured with EPROI was 77.8 ± 17.4% (n = 3) for the 100 mW/cm cohort and 63.0 ± 9.4% (n = 4) for the 60 mW/cm cohort.Conclusion and In conventional PDT, in which the light is administered to the tumor surface, a high irradiance is associated with high oxygen consumption and poor tumor response. In contrast to conventional PDT, the results from this study suggest that a high irradiance, which..."

Oncology • Squamous Cell Carcinoma

Endobronchial Ultrasound Guided Interstitial Photodynamic Therapy in Treating Patients With Locally Advanced Lung Cancer (clinicaltrials.gov) - P1/2 | N=19 | Terminated | Sponsor: Roswell Park Cancer Institute | Trial completion date: Feb 2030 ➔ Jul 2024 | Active, not recruiting ➔ Terminated; was paused by device company for a long period of time

Trial completion date • Trial termination • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

Cutaneous photosensitivity of phototheranostic porphyrin-lipid nanoparticles. (PubMed, Photochem Photobiol) - "Here, we demonstrate in a nonpigmented rat skin model that PS exhibit less severe and shorter-lasting skin photosensitivity compared with an equivalent drug dose of porfimer sodium (PHO), the canonical first-generation PDT drug...By Day 8, the minimal dose of light eliciting any kind of skin reaction was significantly higher with PS than PHO, and by Day 12, there was no detectable skin response with PS. These differences were attributed to altered intradermal distribution and faster clearance of PS vs. PHO in rat skin."

Journal • Dermatology • Oncology

Neoadjuvant Bronchoscopic Photodynamic Therapy to Facilitate Airway and Parenchymal Sparing Lobectomies in Two Patients with Central Airway Neuroendocrine Tumors: A Patient Centered Approach. (PubMed, Photodiagnosis Photodyn Ther) - "While photodynamic therapy has been shown to be an effective stand alone, neoadjuvant, and adjuvant therapy for pulmonary NETs, surgical resection is still required in select patients. We present two cases of in which desired patient outcomes led to the use of neoadjuvant PDT to help facilitate airway and parenchymal sparing lobectomies, thus avoiding more extensive surgical resection and possible long-term morbidity."

Journal • Carcinoid Tumor • Endocrine Cancer • Neuroendocrine Tumor • Oncology • Solid Tumor

The role of ancillary ligands on benzodipyridophenazine-based Ru(II)/Ir(III) complexes in dark and light toxicity against TNBC cells. (PubMed, Dalton Trans) - "Colocalisation and DCFDA studies of Ir1 revealed that it can accumulate in the mitochondria, leading to depolarization of the mitochondrial membrane. These studies confirm that the complex Ir1 is a promising candidate for TNBC treatment in hypoxic tumors, with efficacy comparable to the current PDT drug Photofrin."

Journal • Oncology • Triple Negative Breast Cancer

Porfimer Sodium Interstitial Photodynamic Therapy With or Without Standard of Care Chemotherapy in Treating Patients With Locally Advanced or Recurrent Head and Neck Cancer (clinicaltrials.gov) - P1 | N=5 | Terminated | Sponsor: Roswell Park Cancer Institute | Trial completion date: Nov 2023 ➔ Oct 2024 | Trial primary completion date: Nov 2023 ➔ Oct 2024

Trial completion date • Trial primary completion date • Head and Neck Cancer • Oncology • Solid Tumor

Phase II Trial of Radical Pleurectomy With or Without Intraoperative PDT for Malignant Pleural Mesothelioma (clinicaltrials.gov) - P2 | N=52 | Active, not recruiting | Sponsor: Abramson Cancer Center at Penn Medicine | Recruiting ➔ Active, not recruiting | N=102 ➔ 52

Enrollment change • Enrollment closed • Malignant Pleural Mesothelioma • Mesothelioma • Oncology • Solid Tumor

Supramolecular Organic Framework that Enables Multifunctional Doxorubicin Delivery, Photofrin Post-treatment Phototoxicity Inhibition, and Heparin Neutralization. (PubMed, ACS Appl Bio Mater) - "The supramolecular organic framework has been revealed to have regular intrinsic porosity and adsorb doxorubicin, photofrin, and heparins driven by hydrophobicity and/or ion-pairing electrostatic interactions. In vivo or in vitro assays illustrate that this adsorption leads to efficient intracellular delivery of doxorubicin, which enhances its antitumor efficacy, elimination of photofrin, which inhibits its post-treatment phototoxicity without reducing its photodynamic therapeutic activity, and sequestration of (low-molecular-weight) heparins, which neutralizes their anticoagulation activity more efficiently than clinically used protamine."

Journal • Oncology

Porfimer Sodium Interstitial Photodynamic Therapy With or Without Standard of Care Chemotherapy in Treating Patients With Locally Advanced or Recurrent Head and Neck Cancer (clinicaltrials.gov) - P1 | N=5 | Active, not recruiting | Sponsor: Roswell Park Cancer Institute | Recruiting ➔ Active, not recruiting | N=12 ➔ 5

Enrollment change • Enrollment closed • Metastases • Head and Neck Cancer • Oncology • Solid Tumor

Porfimer Sodium Interstitial Photodynamic Therapy With or Without Standard of Care Chemotherapy in Treating Patients With Locally Advanced or Recurrent Head and Neck Cancer (clinicaltrials.gov) - P1 | N=5 | Terminated | Sponsor: Roswell Park Cancer Institute | Active, not recruiting ➔ Terminated; Low accrual

Metastases • Trial termination • Head and Neck Cancer • Oncology • Solid Tumor

Endobronchial Ultrasound Guided Interstitial Photodynamic Therapy in Treating Patients With Locally Advanced Lung Cancer (clinicaltrials.gov) - P1/2 | N=19 | Active, not recruiting | Sponsor: Roswell Park Cancer Institute | Trial primary completion date: Nov 2023 ➔ Jul 2024

Endobronchial ultrasound • Metastases • Trial primary completion date • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

A Study of PDT in Stage IB Carcinoma Esophagus in Patients Who Are Not Candidates for Surgery or Chemotherapy (ACG 2024) - "All patients received porfimer sodium 2 mg/kg as infusion, followed by EGD with light therapy 48 to 72 hours later... All patients had good response after one treatment. Two patients received a second light application. At 2 year interval all patient had no evidence of local or distant recurrence with negative biopsies and CT scans."

Clinical • Surgery • Esophageal Adenocarcinoma • Esophageal Cancer • Fibrosis • Gastrointestinal Cancer • Gastrointestinal Disorder • Hepatology • Immunology • Oncology • Pain • Squamous Cell Carcinoma • Thermal Injury

A giant macrocycle overcomes the post-treatment phototoxicity of photofrin through host-guest complexation. (PubMed, Chem Commun (Camb)) - "Here we reported a supramolecular sequestration strategy to overcome the post-treatment phototoxicity of photofrin via direct host-guest complexation. Efficient recognition potency of a giant pentaphen[3]arene derivative could favor suppressing sunlight-induced skin damage through weakening the ability of complexed photofrin to generate singlet oxygen."

Journal

Photodynamic therapy using hybrid nanoparticles comprising of upconversion nanoparticles and chlorin e6-bearing pullulan. (PubMed, Biomater Sci) - "The therapeutic efficacy of our hybrid system surpassed that of the clinically available photosensitizer, Photofrin, and hybrid liposomes comprising upconversion nanoparticles and chlorin e6 were employed as control...Notably, our system exhibited 400 times higher PDT activity in tumor-bearing mice compared to the control groups. It also effectively inhibited metastasis."

Journal • Oncology

Photodynamic Therapy to Amplify the Response to Immunotherapy in Patients With Non-small Cell Lung Cancer With Pleural Disease (clinicaltrials.gov) - P1 | N=5 | Active, not recruiting | Sponsor: Roswell Park Cancer Institute | Suspended ➔ Active, not recruiting | N=16 ➔ 5 | Trial completion date: Mar 2025 ➔ Jan 2026 | Trial primary completion date: Mar 2025 ➔ Feb 2024

Enrollment change • Enrollment closed • Trial completion date • Trial primary completion date • Lung Cancer • Malignant Pleural Mesothelioma • Mesothelioma • Non Small Cell Lung Cancer • Oncology • Respiratory Diseases • Solid Tumor • PD-L1

Photostimulated Anticancer Activity of Mitochondria Localized Rhenium(I) Tricarbonyl Complexes Bearing 1H-imidazo[4,5-f][1,10]phenanthroline Ligands Against MDA-MB-231 Cancer Cells. (PubMed, Chemistry) - "Complex ReL6 exhibited more than 9 times higher photo-toxicity in normoxic and hypoxic environment of tumor by inducing 1O2 generation (type II PDT), radical generation triggered by NADH oxidation (type I PDT). This complex is a promising candidate for TNBC treatment in hypoxic tumors, with efficacy comparable to photofrin and have demonstrated CO release ability under UV light irradiation."

Journal • Oncology • Triple Negative Breast Cancer